Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and
 bortezomib improves the progression free survival and the response rate compared to
 historical controls of fludarabine and melphalan alone.
Multiple myeloma is the second most prevalent blood cancer (10%) after non-hodgkin's
 lymphoma. It represents approximately 1% of all cancers and 2% of all cancer deaths. Although
 the peak age of onset of multiple myeloma is 70 years of age, recent statistics indicate both
 increasing incidence and earlier age of onset.

 The historical control 2-year progression-free survival (PFS) is assumed to be 35%. The
 proposed therapy of fludarabine, melphalan and bortezomib is expected to improve the PFS by
 20%.
Inclusion Criteria:

 -  Diagnosis of multiple myeloma

 -  Have a suitable related or unrelated donor

 -  Age ≥18 but <70 yrs

 -  KPS of ≥70%

 -  Recovery from complications of previous therapies

 Exclusion Criteria:

 -  Diagnosis other than multiple myeloma

 -  Chemotherapy or radiotherapy within 21 days of initiating treatment in this study

 -  Prior dose-intense therapy requiring HSC support within 56 days of initiating
 treatment in this study

 -  Uncontrolled bacterial, viral, fungal or parasitic infections

 -  Uncontrolled CNS metastases

 -  Known amyloid deposition in heart

 -  Organ dysfunction

 -  LVEF <40% or cardiac failure not responsive to therapy

 -  FVC, FEV1, or DLCO <50% of predicted and/or receiving supplementary continuous oxygen

 -  Evidence of hepatic synthetic dysfunction, or total bilirubin >2x or AST >3x ULN

 -  Measured creatinine clearance <20 ml/min

 -  Sensory peripheral neuropathy grade 4 within 14 days of enrollment

 -  Karnofsky score <70% unless a result of bone disease directly caused by myeloma

 -  Life expectancy limited by another co-morbid illness

 -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the
 exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
 the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

 -  Female subject is pregnant or breast-feeding (women) or unwilling to use acceptable
 birth control methods (men or women) for twelve months after treatment. Confirmation
 that the subject is not pregnant must be established by a negative serum beta-human
 chorionic gonadotropin (B-hCG) pregnancy test result obtained during screening.
 Pregnancy testing is not required for post-menopausal or surgically sterilized women.

 -  Documented hypersensitivity to fludarabine or melphalan or to bortezomib, boron or
 mannitol or any components of the formulation

 -  Patients unable or unwilling to provide consent

 -  Patient has a sustained platelet count of <30 x 10 9/L within 14 days before
 enrollment

 -  Patient has a sustained absolute neutrophil count of <1.0 x10 9/L within 14 days
 before enrollment

 -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
 Association (NYHA) Class III or IV heart failure uncontrolled angina, severe
 uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
 ischemia or active conduction system abnormalities. Prior to study entry, any ECG
 abnormality at screening has to be documented by the investigator as not medically
 relevant

 -  Patient has received other investigational drugs with 14 days before enrollment

 -  Serious medical or psychiatric illness likely to interfere with participation in this
 clinical study